Aquestive Therapeutics is trading at $4.50, up 6.4%, in pre-market; the catalyst remains unclear. - Shares are up from the October 28 close of $4.23. - No clear company-specific announcement explaining the October 29 pre-market rise surfaced in available search results. - Aquestive recently scheduled third-quarter results for November 3, but that announcement does not establish a cause. Broader U.S. futures were lower and do not explain the move higher either.